Glaucoma lecturer likens preserved drops to processed foods-neither is the healthiest ideal

Article

 

San Diego-“Trying to reduce BAK load is the right thing to do overall,” said Michael Chaglasian, OD, associate professor at Illinois College of Optometry and chief of staff at the Illinois Eye Institute. In his lecture yesterday morning, Preservative vs. Preservative Free Medication in Glaucoma, Dr. Chaglasian made a strong case that there are several deleterious effects of BAK, which should prompt practitioners to avoid them in many cases.

Dr. Chaglasian admitted he wasn’t always concerned about BAK. In fact, he said he didn’t used to pay much attention to ocular surface disease in his glaucoma patients. But, the Dry Eye Work Shop (DEWS) report in 2007 was a wake-up moment for him. The DEWS conclusion that the elimination of preservatives from OTC lubricants was a huge leap forward in ocular surface care made him think more seriously about the effects of preservatives in the glaucoma meds he prescribed. He wondered, “If preservatives play such a big role in ocular surface health, how might they be affecting my glaucoma patients, who use them long term?”

Since effects of preserved drops in glaucoma treatment tend to be subtle and build up over time, they are often overlooked. “But they can have a significant impact,” he said. BAK has several effects on the ocular surface, including:

  • Decreased epithelial cell integrity

  • Increased conjunctival inflammatory cells

  • Loss of goblet cells

  • Reduced tear function

  • Reduced TBUT

Beyond it’s relationship to ocular surface disease, BAK is associated with filtration bleb failure in trabeculectomy patients and inflammatory cell infiltration in the trabecular meshwork. Furthermore, new research also suggests that BAK affects the eyelid muscles, causing incomplete blink and lagophthalmus in animal models.

Dr. Chaglasian recommended that doctors consider the following factors when prescribing topical medications as these contribute to preservative toxicity:

  • Concentration

  • Frequency and duration of use

  • Tear production and clearance

  • Contact lens use

  • Number and type of concurrent meds

  • Type of preservative

Not every patient needs to be treated with BAK-free drops but, he said, clinicians need an evaluation and workup to avoid harming at-risk patients.ODT

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD; and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
© 2025 MJH Life Sciences

All rights reserved.